Analyst Price Targets — COR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 19, 2026 7:07 am | Ryan Halsted | RBC Capital | $330.00 | $316.13 | StreetInsider | RBC Capital Starts Cencora Inc (COR) at Sector Perform |
| August 7, 2026 1:28 pm | — | Morgan Stanley | $346.00 | $323.29 | TheFly | Cencora price target raised to $346 from $342 at Morgan Stanley |
| August 6, 2026 1:18 pm | — | Robert W. Baird | $370.00 | $313.37 | TheFly | Cencora price target raised to $370 from $340 at Baird |
| August 6, 2026 12:35 pm | Kevin Caliendo | UBS | $430.00 | $313.51 | TheFly | Cencora price target raised to $430 from $412 at UBS |
| August 6, 2026 11:49 am | — | Evercore ISI | $350.00 | $317.22 | TheFly | Cencora price target raised to $350 from $330 at Evercore ISI |
| June 10, 2026 9:12 am | — | Barclays | $350.00 | $279.57 | TheFly | Cencora price target lowered to $350 from $425 at Barclays |
| May 11, 2026 10:23 am | Stephen Baxter | Wells Fargo | $331.00 | $261.08 | TheFly | Cencora price target lowered to $331 from $429 at Wells Fargo |
| May 8, 2026 1:12 pm | — | Morgan Stanley | $342.00 | $265.58 | TheFly | Cencora price target lowered to $342 from $400 at Morgan Stanley |
| May 7, 2026 12:05 pm | — | UBS | $412.00 | $256.01 | TheFly | Cencora price target raised to $412 from $410 at UBS |
| April 8, 2026 1:11 pm | — | Evercore ISI | $360.00 | $324.93 | TheFly | Cencora price target lowered to $360 from $420 at Evercore ISI |
Latest News for COR
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene…
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,973 shares of the company's stock, valued at approximately $841,000. Several other
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Advisors Capital Management LLC purchased a new stake in shares of Cencora, Inc. (NYSE: COR) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,644 shares of the company's stock, valued at approximately $748,000. Several other hedge funds and
These healthcare companies can actually benefit from inflation.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.